Dynamic regulation of glucocorticoid signalling in health and disease

Rheumatology

Volumn 51, Issue 3, 2012, Pages 403-412

  Biddie, Simon C ^a   Conway campbell, Becky L ^a   Lightman, Stafford L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Chromatin; Epigenetics; Genetic variation; Glucocorticoid; Glucocorticoid sensitivity; Pulsatile secretion; Rhythms

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE;

ADENOHYPOPHYSIS; ASTHMA; BINDING SITE; CELL SPECIFICITY; CHROMATIN STRUCTURE; CIRCADIAN RHYTHM; COGNITION; DEVELOPMENT; DNA RESPONSIVE ELEMENT; DRUG RESISTANCE; DRUG SENSITIVITY; EPIGENETICS; GENE CONTROL; GENE REGULATORY NETWORK; GENE REPRESSION; GENETIC VARIABILITY; HORMONE RELEASE; HUMAN; HYPOTHALAMUS; INFLAMMATION; METABOLISM; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

DRUG RESISTANCE; GLUCOCORTICOIDS; HUMANS; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84857525459     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker215     Document Type: Review

References (93)

1. Corrigan CJ, Brown PH, Barnes NC et al. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991;144: 1016-25.
2. Kirkham BW, Corkill MM, Davison SC, Panayi GS. Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol 1991;18:821-5.
3. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121: 255-60.
4. Greenstein B. Steroid resistance: implications for lupus. Lupus 1994;3:143.
5. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111:3-22, quiz 23.
6. Kaspers GJ, Pieters R, Klumper E, De Waal FC, Veerman AJ. Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma 1994;13:187-201.
7. Rigaud G, Roux J, Pictet R, Grange T. In vivo footprinting of rat TAT gene: dynamic interplay between the glucocorticoid receptor and a liver-specific factor. Cell 1991;67: 977-86.
8. Zaret KS, Yamamoto KR. Reversible and persistent changes in chromatin structure accompany activation of a glucocorticoid-dependent enhancer element. Cell 1984; 38:29-38.
9. Richard-Foy H, Hager GL. Sequence-specific positioning of nucleosomes over the steroid-inducible MMTV promoter. EMBO J 1987;6:2321-8.
10. John S, Sabo PJ, Johnson TA et al. Interaction of the glucocorticoid receptor with the chromatin landscape. Mol Cell 2008;29:611-24.
11. John S, Sabo PJ, Thurman RE et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 2011;43:264-8.
12. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR. Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 2007;3:e94.
13. John S, Johnson TA, Sung MH et al. Kinetic complexity of the global response to glucocorticoid receptor action. Endocrinology 2009;150:1766-74.
14. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006;126:789-99.
15. Biddie SC. Chromatin architecture and the regulation of nuclear receptor inducible transcription. J Neuroendocrinol 2011;23:94-106.
16. Bird A. Perceptions of epigenetics. Nature 2007;447: 396-8.
17. Lightman SL, Conway-Campbell BL. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci 2010;11:710-8.
18. Windle RJ, Wood SA, Lightman SL, Ingram CD. The pulsatile characteristics of hypothalamo-pituitary-adrenal activity in female Lewis and Fischer 344 rats and its relationship to differential stress responses. Endocrinology 1998;139:4044-52.
19. Young EA, Abelson J, Lightman SL. Cortisol pulsatility and its role in stress regulation and health. Front Neuroendocrinol 2004;25:69-76.
20. Henley DE, Russell GM, Douthwaite JA et al. Hypothalamic-pituitary-adrenal axis activation in obstructive sleep apnea: the effect of continuous positive airway pressure therapy. J Clin Endocrinol Metab 2009;94: 4234-42.
21. Perry MG, Kirwan JR, Jessop DS, Hunt LP. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis 2009;68:63-8.
22. Windle RJ, Wood SA, Kershaw YM, Lightman SL, Ingram CD, Harbuz MS. Increased corticosterone pulse frequency during adjuvant-induced arthritis and its relationship to alterations in stress responsiveness. J Neuroendocrinol 2001;13:905-11.
23. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984;5:25-44.
24. Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986;233:652-4.
25. Chowdrey HS, Larsen PJ, Harbuz MS et al. Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. Br J Pharmacol 1995;116:2417-24.
26. Sarlis NJ, Stephanou A, Knight RA, Lightman SL, Chowdrey HS. Effects of glucocorticoids and chronic inflammatory stress upon anterior pituitary interleukin-6 mRNA expression in the rat. Br J Rheumatol 1993;32: 653-7.
27. Chover-Gonzalez AJ, Harbuz MS, Lightman SL. Effect of adrenalectomy and stress on interleukin-1 beta-mediated activation of hypothalamic corticotropin-releasing factor mRNA. J Neuroimmunol 1993;42:155-60.
28. Perretti M, Mugridge KG, Becherucci C, Parente L. Evidence that interleukin-1 and lipoxygenase metabolites mediate the lethal effect of complete Freund's adjuvant in adrenalectomized rats. Lymphokine Cytokine Res 1991; 10:239-43.
29. Yang YH, Hutchinson P, Leech M, Morand EF. Exacerbation of adjuvant arthritis by adrenalectomy is associated with reduced leukocyte lipocortin 1. J Rheumatol 1997;24:1758-64.
30. Sarlis NJ, Chowdrey HS, Stephanou A, Lightman SL. Chronic activation of the hypothalamo-pituitary-adrenal axis and loss of circadian rhythm during adjuvant-induced arthritis in the rat. Endocrinology 1992;130:1775-9.
31. Silverman MN, Sternberg EM. Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. Neuroimmunomodulation 2008; 15:19-28.
32. Venkataraman S, Munoz R, Candido C, Witchel SF. The hypothalamic-pituitary-adrenal axis in critical illness. Rev Endocr Metab Disord 2007;8:365-73.
33. Harbuz MS, Jessop DS. Is there a defect in cortisol production in rheumatoid arthritis? Rheumatology 1999; 38:298-302.
34. Buttgereit F, Doering G, Schaeffler A et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis [CAPRA-1]: a double-blind, randomised controlled trial. Lancet 2008;371:205-14.
35. Conway-Campbell BL, Sarabdjitsingh RA, McKenna MA et al. Glucocorticoid ultradian rhythmicity directs cyclical gene pulsing of the clock gene period 1 in rat hippocampus. J Neuroendocrinol 2010;22: 1093-100.
36. Stavreva DA, Wiench M, John S et al. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol 2009;11: 1093-102.
37. Biddie SC, Hager GL. Glucocorticoid receptor dynamics and gene regulation. Stress 2009;12:193-205.
38. Boyle AP, Davis S, Shulha HP et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 2008;132:311-22.
39. Sabo PJ, Kuehn MS, Thurman R et al. Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat Methods 2006;3:511-8.
40. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
41. Schule R, Muller M, Kaltschmidt C, Renkawitz R. Many transcription factors interact synergistically with steroid receptors. Science 1988;242:1418-20.
42. Cordingley MG, Hager GL. Binding of multiple factors to the MMTV promoter in crude and fractionated nuclear extracts. Nucleic Acids Res 1988;16:609-28.
43. Archer TK, Cordingley MG, Wolford RG, Hager GL. Transcription factor access is mediated by accurately positioned nucleosomes on the mouse mammary tumor virus promoter. Mol Cell Biol 1991;11:688-98.
44. Belikov S, Astrand C, Wrange O. FoxA1 binding directs chromatin structure and the functional response of a glucocorticoid receptor-regulated promoter. Mol Cell Biol 2009;29:5413-25.
45. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 1990;249:1266-72.
46. Tsai SY, Carlstedt-Duke J, Weigel NL et al. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell 1988; 55:361-9.
47. Wrange O, Eriksson P, Perlmann T. The purified activated glucocorticoid receptor is a homodimer. J Biol Chem 1989;264:5253-9.
48. Firzlaff JM, Diggelmann H. Dexamethasone increases the number of RNA polymerase II molecules transcribing integrated mouse mammary tumor virus DNA and flanking mouse sequences. Mol Cell Biol 1984;4: 1057-62.
49. Fryer CJ, Archer TK. Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature 1998;393:88-91.
50. Chakravarti D, LaMorte VJ, Nelson MC et al. Role of CBP/ P300 in nuclear receptor signalling. Nature 1996;383: 99-103.
51. Ito T, Ikehara T, Nakagawa T, Kraus WL, Muramatsu M. p300-mediated acetylation facilitates the transfer of histone H2A-H2B dimers from nucleosomes to a histone chaperone. Genes Dev 2000;14:1899-907.
52. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993;72:73-84.
53. Dechassa ML, Sabri A, Pondugula S et al. SWI/SNF has intrinsic nucleosome disassembly activity that is dependent on adjacent nucleosomes. Mol Cell 2010;38:590-602.
54. Bouazoune K, Miranda TB, Jones PA, Kingston RE. Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF. Nucleic Acids Res 2009;37:5279-94.
55. Reinke H, Horz W. Histones are first hyperacetylated and then lose contact with the activated PHO5 promoter. Mol Cell 2003;11:1599-607.
56. Becker M, Baumann C, John S et al. Dynamic behavior of transcription factors on a natural promoter in living cells. EMBO Rep 2002;3:1188-94.
57. McNally JG, Muller WG, Walker D, Wolford R, Hager GL. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science 2000;287:1262-5.
58. Nagaich AK, Walker DA, Wolford R, Hager GL. Rapid periodic binding and displacement of the glucocorticoid receptor during chromatin remodeling. Mol Cell 2004;14: 163-74.
59. Fletcher TM, Xiao N, Mautino G et al. ATP-dependent mobilization of the glucocorticoid receptor during chromatin remodeling. Mol Cell Biol 2002;22:3255-63.
60. Conway-Campbell BL, Hager GL, Lightman SL. Molecular dynamics of ultradian glucocorticoid receptor action. Mol Cell Endocrinol 2011, in press.
61. Conway-Campbell BL, George CL, Pooley JR et al. The HSP90 molecular chaperone cycle regulates cyclical transcriptional dynamics of the glucocorticoid receptor and its co-regulatory molecules CBP/P300 during ultradian ligand treatment. Mol Endocrinol 2011;25: 944-54.
62. George CL, Pooley JR, Knight DM, Lightman SL, Conway-Campbell BL. Ultradian glucocorticoid exposure results in rapid & distinct cycles of transcriptional co-activator protein recruitment and acetylation at the Period 1 promoter. In: The 93rd Annual Meeting of the Endocrine Society, Boston, 2011.
63. Yang-Yen HF, Chambard JC, Sun YL et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990;62:1205-15.
64. Schule R, Rangarajan P, Kliewer S et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 1990;62:1217-26.
65. Caldenhoven E, Liden J, Wissink S et al. Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 1995;9:401-12.
66. Adler S, Waterman ML, He X, Rosenfeld MG. Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain. Cell 1988;52:685-95.
67. Reichardt HM, Tuckermann JP, Gottlicher M et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 2001;20:7168-73.
68. Reichardt HM, Kaestner KH, Tuckermann J et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-41.
69. Luecke HF, Yamamoto KR. The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev 2005;19:1116-27.
70. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000;14:2314-29.
71. Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009;3:235-43.
72. Aikawa Y, Morimoto K, Yamamoto T et al. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat Biotechnol 2008;26:817-23.
73. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90.
74. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
75. Jacques E, Semlali A, Boulet LP, Chakir J. AP-1 overexpression impairs corticosteroid inhibition of collagen production by fibroblasts isolated from asthmatic subjects. Am J Physiol Lung Cell Mol Physiol 2010;299: L281-7.
76. Ralph JA, Ahmed AU, Santos LL et al. Identification of NURR1 as a mediator of MIF signaling during chronic arthritis: effects on glucocorticoid-induced MKP1. Am J Pathol 2010;177:2366-78.
77. Beaulieu E, Ngo D, Santos L et al. Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. Arthritis Rheum 2010;62:2651-61.
78. Yang N, Zhang W, Shi XM. Glucocorticoid-induced leucine zipper [GILZ] mediates glucocorticoid action and inhibits inflammatory cytokine-induced COX-2 expression. J Cell Biochem 2008;103:1760-71.
79. Beck IM, Vanden Berghe W, Vermeulen L, Yamamoto KR, Haegeman G, De Bosscher K. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr Rev 2009;30: 830-82.
80. Vinson C, Acharya A, Taparowsky EJ. Deciphering B-ZIP transcription factor interactions in vitro and in vivo. Biochim Biophys Acta 2006;1759:4-12.
81. Rauch A, Seitz S, Baschant U et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010;11:517-31.
82. Rauch A, Gossye V, Bracke D et al. An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J 2011;25:1323-32.
83. Qiu Y, Zhao Y, Becker M et al. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell 2006;22:669-79.
84. Lamberts SW, Huizenga AT, de Lange P, de Jong FH, Koper JW. Clinical aspects of glucocorticoid sensitivity. Steroids 1996;61:157-60.
85. New MI, Nimkarn S, Brandon DD et al. Resistance to multiple steroids in two sisters. J Steroid Biochem Mol Biol 2001;76:161-6.
86. Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004;11(Suppl. 1):S45-55.
87. Rodriguez-Nieto S, Canada A, Pros E et al. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Hum Mutat 2011;32:E1999-2017.
88. Rahimov F, Marazita ML, Visel A et al. Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. Nat Genet 2008;40:1341-7.
89. McDaniell R, Lee BK, Song L et al. Heritable individual-specific and allele-specific chromatin signatures in humans. Science 2010;328:235-9.
90. Kasowski M, Grubert F, Heffelfinger C et al. Variation in transcription factor binding among humans. Science 2010;328:232-5.
91. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009;324:407-10.
92. Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004;7: 847-8.
93. McGowan PO, Sasaki A, D'Alessio AC et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009;12: 342-8.VIJAYker215